A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha release from LPS-activated human monocytes and macrophages

A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha release from LPS-activated human monocytes and macrophages

<p>Abstract</p> <p>Background</p> <p>The cytoprotective nature of nitric oxide (NO) led to development of NO-aspirins in the hope of overcoming the gastric side-effects of aspirin. However, the NO moiety gives these hybrids potential for actions further to their aspirin...

Full description

Bibliographic Details
Main Authors: Fox Sarah, Gasco Alberto, Fruttero Roberta, Cena Clara, Lazzarato Loretta, Sheldrake Tara A, Marcarino Paolo, Turnbull Catriona M, Megson Ian L, Rossi Adriano G
Format: Article
Language:English
Published: BMC 2008-07-01
Series:Journal of Inflammation
Online Access:http://www.journal-inflammation.com/content/5/1/12

Internet

http://www.journal-inflammation.com/content/5/1/12

Similar Items